{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "EUR", "exchange": "FRA", "shortName": "CHINOOK THERAP.  DL-,0001", "longName": "Chinook Therapeutics, Inc.", "messageBoardId": "finmb_634057733", "exchangeTimezoneName": "Europe/Berlin", "exchangeTimezoneShortName": "CEST", "gmtOffSetMilliseconds": 7200000, "market": "dr_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 20.8, "marketState": "REGULAR", "fiftyTwoWeekHighChangePercent": -0.18750004, "fiftyTwoWeekLow": 11.8, "fiftyTwoWeekHigh": 25.6, "earningsTimestamp": 1683662401, "earningsTimestampStart": 1691438400, "earningsTimestampEnd": 1691784000, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.75, "epsForward": -3.27, "epsCurrentYear": -3.52, "priceEpsCurrentYear": -5.9090905, "sharesOutstanding": 65846200, "bookValue": 6.75, "fiftyDayAverage": 20.104, "fiftyDayAverageChange": 0.69599915, "fiftyDayAverageChangePercent": 0.034619935, "twoHundredDayAverage": 21.148, "twoHundredDayAverageChange": -0.34800148, "twoHundredDayAverageChangePercent": -0.016455526, "marketCap": 1388659968, "forwardPE": -6.360856, "priceToBook": 3.0814815, "sourceInterval": 15, "exchangeDataDelayedBy": 15, "averageAnalystRating": "1.5 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683892036, "regularMarketDayHigh": 21.2, "regularMarketDayRange": "20.6 - 21.2", "regularMarketDayLow": 20.6, "regularMarketVolume": 20, "regularMarketPreviousClose": 20.8, "bid": 21.0, "ask": 21.4, "fullExchangeName": "Frankfurt", "financialCurrency": "USD", "regularMarketOpen": 20.8, "averageDailyVolume3Month": 0, "averageDailyVolume10Day": 0, "fiftyTwoWeekLowChange": 8.999999, "fiftyTwoWeekLowChangePercent": 0.76271176, "fiftyTwoWeekRange": "11.8 - 25.6", "fiftyTwoWeekHighChange": -4.800001, "firstTradeDateMilliseconds": 1601964000000, "symbol": "290A.F"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "400 Fairview Avenue North", "address2": "Suite 900", "city": "Seattle", "state": "WA", "zip": "98109", "country": "United States", "phone": "206 485 7241", "website": "https://www.chinooktx.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.", "fullTimeEmployees": 214, "companyOfficers": [{"maxAge": 1, "name": "Mr. Eric L. Dobmeier J.D.", "age": 53, "title": "Pres, CEO & Director", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 972194, "fmt": "972.19k", "longFmt": "972,194"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 16683459, "fmt": "16.68M", "longFmt": "16,683,459"}}, {"maxAge": 1, "name": "Mr. Tom  Frohlich", "age": 46, "title": "Chief Operating Officer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": {"raw": 627444, "fmt": "627.44k", "longFmt": "627,444"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 1476702, "fmt": "1.48M", "longFmt": "1,476,702"}}, {"maxAge": 1, "name": "Mr. Andrew James King D.V.M., Ph.D.", "age": 42, "title": "Chief Scientific Officer", "yearBorn": 1980, "fiscalYear": 2022, "totalPay": {"raw": 651476, "fmt": "651.48k", "longFmt": "651,476"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 3397145, "fmt": "3.4M", "longFmt": "3,397,145"}}, {"maxAge": 1, "name": "Mr. Eric H. Bjerkholt M.B.A.", "age": 62, "title": "Chief Financial Officer", "yearBorn": 1960, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Sukhi  Thethy", "title": "Sr. VP of Fin. & Accounting", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Noopur Batsha Liffick", "title": "Sr. VP of Investor Relations & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kirk D. Schumacher J.D.", "title": "Sr. VP & Gen. Counsel", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Jodi  Jamieson", "title": "Sr. VP of HR", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Alan  Glicklich M.D.", "age": 59, "title": "Exec. Officer", "yearBorn": 1963, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Delphine  Imbert Ph.D.", "title": "Sr. VP of CMC & Technical Operations", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 10, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}